Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Avaliação Justa
O PE mais recente da empresa é 11.66, em uma faixa percentil média de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 35.15M ações, uma redução de 11.16% em relação ao trimestre anterior.
Baixa Atividade de Mercado
A empresa tem menor interesse dos investidores, com uma taxa de giro de 20 dias de -0.19.